Key Financial Metrics
Revenue
₹9,050 Cr
23%
Profit
₹1,581 Cr
Q1 2025
EPS
₹334
135%
Market Cap
₹1,03,430 Cr
Current
Dividend
₹40
Per Share
Cash Reserves
₹2,454 Cr
On Hand
Financial Health
Debt Ratio: 3%
Financial Strength
- Low debt (3%)
- Strong cash position
- 5 years consistent growth
EPS Growth
Business Segments
Click on a segment for details
Geographic Presence
Russia
United States
Germany
India
Other Global Markets
SWOT Analysis
Strengths
- Strong financial position
- Consistent 5-year growth
- Experienced leadership
- Diversified product portfolio
- Global market presence
Weaknesses
- Underperforming subsidiaries
- Lacks clear competitive moat
- Vulnerability to price competition
Opportunities
- New drug development
- Strategic acquisitions
- Partnership with Nestlé India
- Global market expansion
Threats
- Price competition in generics
- Currency fluctuations
- Economic uncertainties
- R&D risks
Warren Buffett Analysis
What He'd Like
- Simple business model
- Strong cash position
- Low debt
- Experienced management
What He'd Be Worried About
- Lacks clear competitive moat
- Unpredictable future earnings
- Price competition vulnerability
Strategic Initiatives
Acquisition in Germany
Expanding European presence through strategic acquisition
Partnership with Nestlé India
Joint venture for health products development
New Cancer Drug Launch in US
Expanding product portfolio in oncology segment